S62527
Open-label induction and maintenance study of oral CP-690,550 (Tofacitinib) in children with moderately to severely active ulcerative colitis.
S65366
A randomized, double-blind, phase 3 study to evaluate the efficacy and safety of vedolizumab intravenous as maintenance therapy in pediatric subjects with moderately to severely active crohn’s disease who achieved clinical response following open–label vedolizumab intravenous therapy.
S65365
A randomized, double-blind, phase 3 study to evaluate the efficacy and safety of vedolizumab intravenous as maintenance therapy in pediatric subjects with moderately to severely active ulcerative colitis who achieved clinical response following open–label vedolizumab intravenous therapy.
S66432
A phase 3, multicenter, open-label, basket, long-term extension study of ustekinumab in pediatric clinical study participants (2 to <18 years of age).
IM047023
A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral ozanimod (rpc1063) in pediatric participants with moderately to severely active crohn’s disease with an inadequate response to conventional therapy
APD334-207
An open-label, single-arm study to evaluate the efficacy, pharmacokinetics, and safety of etrasimod in adolescent subjects with moderately to severely active ulcerative colitis
CNTO1275puc3001
a phase 3 study of the efficacy, safety and pharmacokinetics of ustekinumab as open[1]label intravenous induction treatment followed by randomized double-blind subcutaneous ustekinumab maintenance in pediatric participants with moderately to severely active ulcerative colitis
CNTO1275CRD3004
A phase 3 study of the efficacy, safety, and pharmacokinetics of ustekinumab as open-label intravenous induction treatment followed by randomized double-blind subcutaneous ustekinumab maintenance in pediatric participants with moderately to severely active crohn’s disease
IM047-001
A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral ozanimod (rpc1063) in pediatric subjects with moderately to severely active ulcerative colitis with an inadequate response to conventional therapy
MLN0002-3029
A phase 3b extension study to evaluate the long-term safety of vedolizumab intravenous in pediatric patients with ulcerative colitis or crohn’s disease.
Laatste aanpassing:
27 juni 2023